The House on Wednesday (July 20) passed by a vote of 220-207 a six-bill funding package that gives FDA $3.6 billion in discretionary funding for fiscal 2023, an increase of $341 million over fiscal 2022 levels. The legislative package comprises six of the 12 funding bills, including the FDA-agriculture bill; it does not include the HHS spending bill. The legislation offers an increase of $64 million for drug and device activities, including for FDA’s efforts to manage the opioid crisis,...